Evaluation effects of treatment with IL-6R inhibitor on clinical response and biomarkers in patients with rheumatoid arthritis (RA) not responding to DMARDs and/or a first biological agent. [Valutazione degli effetti del trattamento con un inibitore dell'IL-6R sulla risposta clinica e sui biomarcatori in pazienti con artrite reumatoide (AR) non responsiva ai DMARDs e/o al primo biologico]

Trial Profile

Evaluation effects of treatment with IL-6R inhibitor on clinical response and biomarkers in patients with rheumatoid arthritis (RA) not responding to DMARDs and/or a first biological agent. [Valutazione degli effetti del trattamento con un inibitore dell'IL-6R sulla risposta clinica e sui biomarcatori in pazienti con artrite reumatoide (AR) non responsiva ai DMARDs e/o al primo biologico]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Apr 2013 Planned end date changed from 5 May 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov
    • 18 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01835613).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top